189 related articles for article (PubMed ID: 23587424)
21. The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects.
Butelman ER; Rus S; Prisinzano TE; Kreek MJ
Psychopharmacology (Berl); 2010 Jun; 210(2):253-62. PubMed ID: 20084367
[TBL] [Abstract][Full Text] [Related]
22. Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.
Béguin C; Potuzak J; Xu W; Liu-Chen LY; Streicher JM; Groer CE; Bohn LM; Carlezon WA; Cohen BM
Bioorg Med Chem Lett; 2012 Jan; 22(2):1023-6. PubMed ID: 22204910
[TBL] [Abstract][Full Text] [Related]
23. Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice.
Ansonoff MA; Zhang J; Czyzyk T; Rothman RB; Stewart J; Xu H; Zjwiony J; Siebert DJ; Yang F; Roth BL; Pintar JE
J Pharmacol Exp Ther; 2006 Aug; 318(2):641-8. PubMed ID: 16672569
[TBL] [Abstract][Full Text] [Related]
24. Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid.
Butelman ER; Prisinzano TE; Deng H; Rus S; Kreek MJ
J Pharmacol Exp Ther; 2009 Feb; 328(2):588-97. PubMed ID: 19001155
[TBL] [Abstract][Full Text] [Related]
25. Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents.
Walentiny DM; Vann RE; Warner JA; King LS; Seltzman HH; Navarro HA; Twine CE; Thomas BF; Gilliam AF; Gilmour BP; Carroll FI; Wiley JL
Psychopharmacology (Berl); 2010 Jun; 210(2):275-84. PubMed ID: 20354680
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats.
Baker LE; Panos JJ; Killinger BA; Peet MM; Bell LM; Haliw LA; Walker SL
Psychopharmacology (Berl); 2009 Apr; 203(2):203-11. PubMed ID: 19153716
[TBL] [Abstract][Full Text] [Related]
27. Opioid receptor probes derived from cycloaddition of the hallucinogen natural product salvinorin A.
Lozama A; Cunningham CW; Caspers MJ; Douglas JT; Dersch CM; Rothman RB; Prisinzano TE
J Nat Prod; 2011 Apr; 74(4):718-26. PubMed ID: 21338114
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues.
Lee DY; Karnati VV; He M; Liu-Chen LY; Kondaveti L; Ma Z; Wang Y; Chen Y; Beguin C; Carlezon WA; Cohen B
Bioorg Med Chem Lett; 2005 Aug; 15(16):3744-7. PubMed ID: 15993589
[TBL] [Abstract][Full Text] [Related]
29. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: role of the furan in affinity for opioid receptors.
Simpson DS; Lovell KM; Lozama A; Han N; Day VW; Dersch CM; Rothman RB; Prisinzano TE
Org Biomol Chem; 2009 Sep; 7(18):3748-56. PubMed ID: 19707679
[TBL] [Abstract][Full Text] [Related]
30. The hallucinogen derived from Salvia divinorum, salvinorin A, has kappa-opioid agonist discriminative stimulus effects in rats.
Willmore-Fordham CB; Krall DM; McCurdy CR; Kinder DH
Neuropharmacology; 2007 Sep; 53(4):481-6. PubMed ID: 17681558
[TBL] [Abstract][Full Text] [Related]
31. Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability.
Sherwood AM; Crowley RS; Paton KF; Biggerstaff A; Neuenswander B; Day VW; Kivell BM; Prisinzano TE
J Med Chem; 2017 May; 60(9):3866-3878. PubMed ID: 28376298
[TBL] [Abstract][Full Text] [Related]
32. Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo.
Butelman ER; Caspers M; Lovell KM; Kreek MJ; Prisinzano TE
J Pharmacol Exp Ther; 2012 Jun; 341(3):802-8. PubMed ID: 22434677
[TBL] [Abstract][Full Text] [Related]
33. O6C-20-nor-salvinorin A is a stable and potent KOR agonist.
Hirasawa S; Cho M; Brust TF; Roach JJ; Bohn LM; Shenvi RA
Bioorg Med Chem Lett; 2018 Sep; 28(16):2770-2772. PubMed ID: 29426768
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and in vitro pharmacological studies of new C(4)-modified salvinorin A analogues.
Lee DY; He M; Liu-Chen LY; Wang Y; Li JG; Xu W; Ma Z; Carlezon WA; Cohen B
Bioorg Med Chem Lett; 2006 Nov; 16(21):5498-502. PubMed ID: 16945525
[TBL] [Abstract][Full Text] [Related]
35. Salvinorin a and related compounds as therapeutic drugs for psychostimulant-related disorders.
dos Santos RG; Crippa JA; Machado-de-Sousa JP; Hallak JE
Curr Drug Abuse Rev; 2014; 7(2):128-32. PubMed ID: 25563442
[TBL] [Abstract][Full Text] [Related]
36. Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors.
Zhang Y; Butelman ER; Schlussman SD; Ho A; Kreek MJ
Psychopharmacology (Berl); 2005 May; 179(3):551-8. PubMed ID: 15682306
[TBL] [Abstract][Full Text] [Related]
37. Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum.
Johnson MW; MacLean KA; Reissig CJ; Prisinzano TE; Griffiths RR
Drug Alcohol Depend; 2011 May; 115(1-2):150-5. PubMed ID: 21131142
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological evaluation of C-2 halogenated analogs of salvinorin A.
Lee DY; Yang L; Xu W; Deng G; Guo L; Liu-Chen LY
Bioorg Med Chem Lett; 2010 Oct; 20(19):5749-52. PubMed ID: 20801035
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological evaluation of 2-alkyl-2-methoxymethyl-salvinorin ethers as selective κ-opioid receptor agonists.
Lee DY; Deng G; Ma Z; Xu W; Yang L; Liu J; Dai R; Liu-Chen LY
Bioorg Med Chem Lett; 2015 Oct; 25(20):4689-92. PubMed ID: 26330078
[TBL] [Abstract][Full Text] [Related]
40. Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.
Béguin C; Duncan KK; Munro TA; Ho DM; Xu W; Liu-Chen LY; Carlezon WA; Cohen BM
Bioorg Med Chem; 2009 Feb; 17(3):1370-80. PubMed ID: 19147366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
